Latest Breaking News On - Clinical translational research - Page 3 : comparemela.com

Study explores the influence of social networks on oral health outcomes

Study explores the influence of social networks on oral health outcomes
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesBrenda heatonClinical translational researchTranslational researchSocial network influencesOral health outcomesWomen livingPublic housingModeling social network influences

Novartis Pharma AG: Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease

United statesSan antonioFrance generalComunidad autonoma de catalunaSamir shahNicole zinsli sommRichard jarvisIsabella zinckSatoshi sugimotoDennisj slamonShreeram aradhyeMarlena abdinoorJulie masowParag mahantiFran viscoMary carmichael

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.

University of chicagoUnited statesRita nandaLos angelesDennisj slamonUniversity of chicago medicineClinical translational researchAmerican society of clinical oncology annual meetingJonsson comprehensive cancer centerWomen cancer research programBreast oncology programClinical oncology annualTranslational researchCancer research programComprehensive cancer centerRecurrence score

Ribociclib Lowers Risk of Disease Recurrence by 25% for Early Breast Cancer

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

United statesShreeram aradhyeDennisj slamonRibociclib kisqaliTranslational research in oncologyAmerican society of clinical oncology annual meetingClinical translational researchGlobal drug developmentClinical oncology annualTranslational researchCalifornia los angelesJonsson comprehensive cancer center

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2-.

San antonioUnited statesFrance generalComunidad autonoma de catalunaFran viscoDennisj slamonPrnewswire novartisShreeram aradhyeJonsson comprehensive cancer centerEuropean society for medical oncologyAmerican society of clinical oncologyNational breast cancer coalitionDrug administrationGlobal drug developmentExchange commissionAkershus university hospital